The USFDA has approved a new therapy for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This advanced therapy can be taken at home without hospitalization and intravenous infusions. The therapy consists of a combination of decitabine and cedazuridine in a tablet form that needs to be taken once daily for five consecutive days in a 28-day cycle . The approval is based on a clinical trial that compared the efficacy and safety of this oral formulation of the combination drug with intravenous decitabine. The study showed similar drug concentrations in both groups.
Additionally, half of the patients no longer required transfusion during an 8-week period. The safety profile was comparable between the two groups. The reported side effects include fatigue, constipation, hemorrhage, muscle pain, mucositis, arthralgia, fever, and low WBC count . The therapy is…
